GeneDx Holdings (WGS) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.01
- EPS estimate
- −$0.19
- EPS surprise
- +105.32%
- Revenue surprise
- +3.09%
- Revenue
- $114.4M
- Revenue estimate
- $111.0M
- Reported
- Aug 3, 2026
GeneDx reported Q2 2026 results on August 3, 2026. Earnings per share came in at $0.01, a small profit against a consensus estimate of a $0.19 loss, a beat of 105.32%. Revenue was $114.4 million, ahead of the $111.0 million estimate. Compared with Q2 2025, revenue grew about 11% from $102.7 million, but EPS fell from $0.50. It followed a Q1 2026 loss of $0.28 per share.
Revenue grew from $43.1 million in Q1 2023 to a high in the table of $121.0 million in Q4 2025. Annual revenue rose from $203.2 million in 2023 to $305.1 million in 2024 and $427.5 million in 2025. Per-share results moved from a loss of $5.40 in 2023 to earnings of $0.37 in 2024 and $1.41 in 2025. Losses in 2022 were far larger per share, with the deepest at $29.70 in Q4 2022. GeneDx beat the EPS estimate in 15 of the last 20 quarters.
GeneDx reported Q3 between October 28 and October 30 in each of the past three years. That points to late October 2026 for the next report. It will show whether revenue stays above $110 million and whether the Q2 profit carries into Q3.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 3, 2026 | −$0.19 | $0.01 | +105.32% | $114.4M | SEC |
| Q1 2026 | May 4, 2026 | −$0.02 | −$0.28 | −1766.67% | $102.3M | SEC |
| Q4 2025 | Feb 23, 2026 | $0.12 | $0.14 | +16.86% | $121.0M | SEC |
| Q3 2025 | Oct 28, 2025 | $0.42 | $0.49 | +15.87% | $116.7M | SEC |
| Q2 2025 | Jul 29, 2025 | $0.12 | $0.50 | +331.78% | $102.7M | SEC |
| Q1 2025 | Apr 30, 2025 | $0.06 | $0.28 | +365.65% | $87.1M | SEC |
| Q4 2024 | Feb 18, 2025 | $0.16 | $0.77 | +372.67% | $95.6M | SEC |
| Q3 2024 | Oct 29, 2024 | −$0.22 | $0.04 | +118.65% | $76.6M | SEC |
| Q2 2024 | Jul 30, 2024 | −$0.30 | −$0.11 | +64.37% | $70.5M | SEC |
| Q1 2024 | Apr 29, 2024 | −$0.67 | −$0.33 | +50.58% | $62.4M | SEC |
| Q4 2023 | Feb 20, 2024 | −$0.65 | −$0.49 | +24.87% | $58.1M | SEC |
| Q3 2023 | Oct 30, 2023 | −$1.31 | −$0.82 | +37.37% | $53.3M | SEC |
| Q2 2023 | Aug 8, 2023 | −$1.31 | −$1.65 | −25.51% | $48.7M | SEC |
| Q1 2023 | May 9, 2023 | −$1.57 | −$2.44 | −54.91% | $43.1M | SEC |
| Q4 2022 | Mar 14, 2023 | −$6.08 | −$29.70 | −388.13% | $61.4M | SEC |
| Q3 2022 | Nov 14, 2022 | −$6.82 | −$6.65 | +2.42% | $83.2M | SEC |
| Q2 2022 | Aug 15, 2022 | −$6.77 | −$7.13 | −5.34% | $36.2M | SEC |
| Q1 2022 | May 12, 2022 | −$10.56 | −$10.23 | +3.13% | $53.9M | SEC |
| Q4 2021 | Mar 14, 2022 | −$8.50 | −$5.61 | +34.00% | $57.8M | SEC |
| Q3 2021 | Nov 15, 2021 | −$6.16 | $4.95 | +180.36% | $43.2M | SEC |
Quarterly revenue
Frequently asked questions
When did GeneDx Holdings (WGS) last report earnings?
GeneDx Holdings last reported on Aug 3, 2026, covering fiscal Q2 2026.
Did WGS beat earnings estimates?
Yes. GeneDx Holdings reported EPS of $0.01 for Q2 2026 against a −$0.19 estimate — a 105.32% beat.
How much revenue did WGS report last quarter?
GeneDx Holdings reported $114.4M in revenue for Q2 2026, against a consensus estimate of $111.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.